A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Brief description of study

If you have been diagnosed with either prostate, lung cancer, breast cancer, ovarian cancer, or urothelial cancer you may qualify to participate in a study to learn about the effects of the study drugs, avelumab (anti-PD-L1 immunotherapy and talazoparib (PARP inhibitor), when given as an investigational combination treatment for your cancer. The goal of this phase 1/2 study is to assess the safety and early signs of efficacy of the avelumab and talazoparib combination in patients with locally advanced (primary or recurrent) or metastatic solid tumors.


Clinical Study Identifier: s17-01353
ClinicalTrials.gov Identifier: NCT03330405
Principal Investigator: David R. Wise
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.